Epigallocatechin-3-gallate (EGCG) in supportive and symptomatic treatment of patients with esophageal cancer

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100050444

Enrollment

Unknown

Registered

2021-08-27

Start date

2021-08-23

Completion date

Unknown

Last updated

2022-05-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Esophageal cancer

Interventions

Experimental group:Oral EGCG therapy

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Diagnosed with clinical cell carcinoma of the esophagus; 2. Aged >=18 years; 3. Eastern Cooperative Oncology Group Status Score (ECOG PS) 0-1; 4. No previous anti-tumor therapy; 5. No esophageal bleeding or fistula; 6. Blood cell count, liver and kidney function are normal; 7. Classified as grade 2 or 3 esophageal obstruction according to CTCAE 5.0.

Exclusion criteria

Exclusion criteria: 1. Breastfeeding or pregnant patients. 2. Known allergy or hypersensitivity to any one of the green tea extracts. 3. Place small bowel feeding tube or endoscopic stent treatment.

Design outcomes

Primary

Measure	Time frame
Safty;Recommended dose;	—

Secondary

Measure	Time frame
Efficiency;Weight change;Change in blood biochemical indicators;	—

Countries

China

Contacts

Public ContactZhao Hanxi

Shandong Cancer Hospital and Institute

zhx87520052@163.com+86 17753128181

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026